Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

BACKGROUND AND OBJECTIVE: The economic assessment of immuno-oncology agents in Chinese patients is limited despite a need for new therapies. Nivolumab is the first immune checkpoint inhibitor approved for the second-line treatment of non-small cell lung cancer (NSCLC) in China, and it significantly...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiao, Luo, Xia, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Zeng, Xiaohui, Tan, Chongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989620/
https://www.ncbi.nlm.nih.gov/pubmed/31679121
http://dx.doi.org/10.1007/s40261-019-00869-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989620/
https://www.ncbi.nlm.nih.gov/pubmed/31679121
http://dx.doi.org/10.1007/s40261-019-00869-3

Ejemplares similares